Autoimmune bullous skin disorders are rare but meaningful chronic inflammatory diseases,
many of which had a poor or devastating prognosis prior to the advent of …

Oral Diseases (2012) 19, 37–45 Inflammatory ulcerative diseases of the oral mucosa are
wide ranging but include especially aphthous and aphthous‐like ulceration, vesiculobullous …

Background The treatment of pemphigus is still challenging and some patients with
pemphigus are unresponsive to conventional immunosuppressive treatments. Rituximab, a …

Background: Epidermolysis bullosa acquisita (EBA) is a rare subepidermal bullous disease.
Long-term remission in this disease is difficult using current treatments, unlike that in …

Importance Immunobullous diseases mediated by IgA are often difficult to manage, but to
date no mechanism has been proposed. Rituximab is an anti-CD20 monoclonal antibody …

To evaluate the long‐term outcomes of rituximab in the treatment of pemphigus and the
influence of disease duration and different dose of rituximab on the clinical response, 45 …

Abstract Purpose of Review Rituximab has transformed the treatment of B-cell malignancies
and rheumatoid arthritis in the past 2 decades. More recently, this anti-CD20 monoclonal …

Epidermolysis bullosa acquisita (EBA) is a rare, chronic, autoimmune, blistering disease
primarily due to circulating IgG autoantibodies to the various domains of type VII collagen …

Mucous membrane pemphigoid (MMP) is an autoimmune blistering, scarring and
occasionally mutilating disease that may progress to blindness or airway obstruction. Over …

We describe a 36-year-old woman with erythematous lesions and well-tense blisters
confined to the face and neck of two months history, without mucosal involvement and no …